ES2768651T3 - Composición farmacéutica sólida - Google Patents
Composición farmacéutica sólida Download PDFInfo
- Publication number
- ES2768651T3 ES2768651T3 ES14787908T ES14787908T ES2768651T3 ES 2768651 T3 ES2768651 T3 ES 2768651T3 ES 14787908 T ES14787908 T ES 14787908T ES 14787908 T ES14787908 T ES 14787908T ES 2768651 T3 ES2768651 T3 ES 2768651T3
- Authority
- ES
- Spain
- Prior art keywords
- tio
- mpos
- ico
- tic
- ica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/235—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids for making foam
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013092171 | 2013-04-25 | ||
| PCT/JP2014/002308 WO2014174846A1 (ja) | 2013-04-25 | 2014-04-24 | 固形医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2768651T3 true ES2768651T3 (es) | 2020-06-23 |
Family
ID=51791434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14787908T Active ES2768651T3 (es) | 2013-04-25 | 2014-04-24 | Composición farmacéutica sólida |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9603804B2 (enExample) |
| EP (1) | EP2990038B1 (enExample) |
| JP (2) | JP5651812B1 (enExample) |
| CN (1) | CN105338982B (enExample) |
| CA (1) | CA2910112C (enExample) |
| ES (1) | ES2768651T3 (enExample) |
| WO (1) | WO2014174846A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105338981B (zh) * | 2013-04-25 | 2017-10-13 | 杏林制药株式会社 | 固体药用组合物 |
| JP6832706B2 (ja) * | 2014-10-23 | 2021-02-24 | 杏林製薬株式会社 | 固形医薬組成物 |
| JP6018334B2 (ja) * | 2014-10-23 | 2016-11-02 | 杏林製薬株式会社 | 固形医薬組成物 |
| JP6031217B1 (ja) * | 2015-06-02 | 2016-11-24 | 杏林製薬株式会社 | 水性液剤 |
| EP3305294A4 (en) * | 2015-06-02 | 2019-02-20 | Kyorin Pharmaceutical Co., Ltd. | AQUEOUS MEDICINE |
| WO2016195020A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ, インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| AU2021236757A1 (en) * | 2020-03-20 | 2022-10-13 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8524001D0 (en) | 1985-09-30 | 1985-11-06 | Glaxo Group Ltd | Pharmaceutical composition |
| ZA87279B (en) | 1986-01-17 | 1987-09-30 | Chugai Pharmaceutical Co Ltd | Method for production of stable nicorandil preparation |
| KR940000232B1 (ko) | 1986-01-17 | 1994-01-12 | 쥬우가이세이야꾸 가부시끼가이샤 | 니코란딜 제제의 안정화 방법 |
| JP2512302B2 (ja) | 1986-03-19 | 1996-07-03 | 中外製薬株式会社 | ニコランジル安定化製剤の製造方法 |
| KR910700043A (ko) | 1988-12-28 | 1991-03-13 | 우에하라 아끼라 | 타정시에 있어서 응력분산 방법 |
| TW284688B (enExample) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| JP2682353B2 (ja) | 1991-11-20 | 1997-11-26 | 武田薬品工業株式会社 | 経口用医薬組成物およびその製造法 |
| JP2006111639A (ja) | 1993-10-21 | 2006-04-27 | Takeda Chem Ind Ltd | 医薬用錠剤 |
| JPH08175996A (ja) | 1994-12-22 | 1996-07-09 | Taiyo Yakuhin Kogyo Kk | ニコランジル安定化固形製剤の製法 |
| JP3119801B2 (ja) | 1995-09-28 | 2000-12-25 | 武田薬品工業株式会社 | ビタミン含有組成物の安定化方法 |
| JPH10245335A (ja) | 1997-02-28 | 1998-09-14 | Dainippon Pharmaceut Co Ltd | 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒 |
| AU3277899A (en) | 1998-03-03 | 1999-09-20 | Dae Woong Chemical Co., Ltd. | Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| AT413647B (de) | 1998-11-26 | 2006-04-15 | Sandoz Ag | Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten |
| DE10048510A1 (de) | 2000-09-29 | 2002-05-16 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
| ATE303149T1 (de) | 2001-02-27 | 2005-09-15 | Ranbaxy Lab Ltd | Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil |
| US7219132B2 (en) | 2001-03-30 | 2007-05-15 | Space Systems/Loral | Dynamic resource allocation architecture for differentiated services over broadband communication networks |
| JP4468701B2 (ja) | 2002-03-18 | 2010-05-26 | 杏林製薬株式会社 | 耐性菌に有効な10−(3−シクロプロピルアミノメチル−1−ピロリジニル)ピリドベンズオキサジンカルボン酸誘導体 |
| ES2297067T3 (es) | 2003-03-19 | 2008-05-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Composiciones farmaceuticas no higroscopicas que contienen acidos quinolinacarboxilicos de hidratados. |
| SG144936A1 (en) | 2003-09-10 | 2008-08-28 | Kyorin Seiyaku Kk | 7-(4-substituted-3-cyclopropylaminomethyl-1- pyrrolidinyl)quinolonecarboxylic acid derivative |
| US20090117205A1 (en) | 2004-07-02 | 2009-05-07 | Daiichi Pharmaceutical Co., Ltd | Quinolone-containing medicinal composition |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| JPWO2006059716A1 (ja) | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
| AR052559A1 (es) | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| WO2006079496A1 (en) | 2005-01-26 | 2006-08-03 | Lek Pharmaceuticals D.D. | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
| JP2006298811A (ja) | 2005-04-20 | 2006-11-02 | Taiyo Yakuhin Kogyo Kk | ゲル化抑制製剤の設計 |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| WO2013145749A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
| WO2013145750A1 (ja) | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
| CN105338981B (zh) * | 2013-04-25 | 2017-10-13 | 杏林制药株式会社 | 固体药用组合物 |
-
2014
- 2014-04-24 ES ES14787908T patent/ES2768651T3/es active Active
- 2014-04-24 JP JP2014541237A patent/JP5651812B1/ja active Active
- 2014-04-24 WO PCT/JP2014/002308 patent/WO2014174846A1/ja not_active Ceased
- 2014-04-24 EP EP14787908.4A patent/EP2990038B1/en active Active
- 2014-04-24 US US14/786,394 patent/US9603804B2/en not_active Expired - Fee Related
- 2014-04-24 CA CA2910112A patent/CA2910112C/en not_active Expired - Fee Related
- 2014-04-24 CN CN201480036231.6A patent/CN105338982B/zh active Active
- 2014-11-17 JP JP2014233012A patent/JP6391436B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2990038B1 (en) | 2019-11-20 |
| EP2990038A4 (en) | 2016-11-16 |
| JP2015078201A (ja) | 2015-04-23 |
| US9603804B2 (en) | 2017-03-28 |
| JP5651812B1 (ja) | 2015-01-14 |
| CA2910112A1 (en) | 2014-10-30 |
| EP2990038A1 (en) | 2016-03-02 |
| US20160067185A1 (en) | 2016-03-10 |
| JPWO2014174846A1 (ja) | 2017-02-23 |
| WO2014174846A1 (ja) | 2014-10-30 |
| CN105338982A (zh) | 2016-02-17 |
| CA2910112C (en) | 2021-02-16 |
| CN105338982B (zh) | 2017-10-10 |
| JP6391436B2 (ja) | 2018-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9815764B2 (en) | Homochiral metal-organic framework with enantiopure pillar[5]arene active domains | |
| US20150057185A1 (en) | Reaction-based fluorescent probe for selective detection of carbon monoxide using metal-mediated carbonylation | |
| Yang et al. | Diastereoselective synthesis of O symmetric heterometallic cubic cages | |
| Chiocchio et al. | Monoamines in the carotid body cells of the cat | |
| Evans et al. | Complete stereocontrol in the synthesis of macrocyclic lanthanide complexes: direct formation of enantiopure systems for circularly polarised luminescence applications | |
| Saliba et al. | Stimulating effect of both 4’‐O‐methylnorbelladine feeding and temporary immersion conditions on galanthamine and lycorine production by Leucojum aestivum L. bulblets | |
| Meijers et al. | Climate stability in central Anatolia during the Messinian Salinity Crisis | |
| CN114014872B (zh) | 青蒿琥酯衍生物及其制备方法和应用 | |
| Sundaresan et al. | Alpha-and beta-adrenergic receptors in proximal tubules of rat kidney | |
| Orue-Etxebarria et al. | Physical and Biostratigraphic analysis of two prospective Paleocene-Eocene boundary stratotypes in the intermediate-deep water Basque basin, western Pyrenees: The Trabakua Pass and Ermua sections. | |
| JPS6054345A (ja) | エナンチオマ−を薄層クロマトグラフイ−分離する方法 | |
| EP3305294A1 (en) | Aqueous drug | |
| Abreu et al. | Characterization of the variation in the imidazole alkaloid profile of Pilocarpus microphyllus in different seasons and parts of the plant by electrospray ionization mass spectrometry fingerprinting and identification of novel alkaloids by tandem mass spectrometry | |
| Hannon et al. | A cheap yet effective chiral stationary phase for chromatographic resolution of metallo-supramolecular helicates | |
| Mallette et al. | The isotopic fractionation of carbon, nitrogen, hydrogen, and oxygen during illicit production of cocaine base in South America | |
| CN107525877B (zh) | 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法 | |
| Grinder-Hansen et al. | Textiles and environment in the showcase containing Saint Canute the Holy († AD 1086): Radiocarbon dating and chemical interactions | |
| US10828324B2 (en) | Production of water-soluble hydrolyzed clinoptilolite fragments | |
| CN104307002B (zh) | 一种适合临床应用的无载体[*i]mibg的制备方法及应用 | |
| Górecki et al. | Circularly Polarized Luminescence From Spontaneous Symmetry Breaking in a Bimetallic Eu–Al Complex | |
| AU720219B2 (en) | New dosage form of hydroxocobalamin and its use in cyanide poisoning | |
| Drabowicz et al. | Optically active spirosulfuranes via nonclassical resolution with 2, 2′-dihydroxy 1, 1′-binaphthol | |
| Antoine Lanfranchi et al. | Enantiomeric differentiation of atropine/hyoscyamine by 13C NMR spectroscopy and its application to Datura stramonium extract | |
| Martin et al. | Synthesis and anticancer activity of ruthenium half-sandwich complexes comprising combined metal centrochirality and planar chirality | |
| Wijeratne et al. | Molecular recognition properties of tartrates and metal‐tartrates in solution and gas phase |